相关实验视频

Updated: Jan 8, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

具有微卫星不稳定性高和BRCA1/2突变的子宫内膜癌的临床特征

Yuping Shan¹, Yan Wang¹, Liying Huang¹

¹Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Frontiers in oncology

|December 22, 2025

概括

具有BRCA1/2突变 (BRCAm) 和微卫星不稳定性高 (MSI-H) 的子宫内膜癌 (EC) 显示了淋巴结转移和复发的增加. 然而,BRCAm不是MSI-H EC.中无进展生存 (PFS) 的独立预后因素.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
癌症研究癌症研究

背景情况:

子宫内膜癌 (EC) 是一种严重的妇科恶性瘤.
微卫星不稳定性高 (MSI-H) 和BRCA1/2突变 (BRCAm) 是关键的分子亚型.
了解EC的临床特征与同时发生的MSI-H和BRCAm对于向治疗和预后至关重要.

研究的目的:

为了确定由微卫星不稳定性高 (MSI-H) 和BRCA1 / 2突变 (BRCAm) 的特征的子宫内膜癌 (EC) 的独特临床特征.
为了比较MSI-H EC患者与没有BRCAm之间的临床特征和生存结果.
在MSI-H EC中评估BRCAm的预后意义.

主要方法:

在2021年3月至2024年12月期间诊断出MSI-H EC的177名患者的回顾性队列研究.
患者被分为只有MSI-H (M组) 和MSI-H与BRCAm (MB组).
分析了临床数据,并使用Kaplan-Meier曲线和Cox回归模型评估了无进展生存期 (PFS).

主要成果:

与M组 (n=149) 相比,MB组 (n=28) 的淋巴结转移率 (14.29%对2.01%) 和复发率 (17.86%对1.34%) 高于M组 (n=149).
腹腔镜手术的发病率较低 (67.86%vs87.25%),免疫治疗的使用率在MB组较高.
卡普兰-梅尔分析显示,两组之间PFS的显著差异 (p=0.006),MB组的结果较差.

结论:

在子宫内膜癌中,BRCAm和MSI-H的同时发生与淋巴结转移的增加和更高的复发率有关.
尽管存在这些关联,但BRCAm并未被确定为影响PFS的独立预后因素,在MSI-H EC的这一队列中.
需要进一步的研究来阐明MSI-H,BRCAm和EC的临床结果之间的复杂相互作用.

关键词:

这就是BRCA1的原因.这就是BRCA2的原因.宫内膜的新生病.同类重组缺陷的同类重组缺陷微卫星的不稳定性

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...